Get the Stockscreener App
324.43
0.43%
0.74
Bio Rad Laboratories Inc stock is traded at $324.43, with a volume of 78,089.
It is up +0.43% in the last 24 hours and down -5.26% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$323.69
Open:
$323.03
24h Volume:
78,089
Relative Volume:
0.30
Market Cap:
$9.06B
Revenue:
$2.58B
Net Income/Loss:
$-778.69M
P/E Ratio:
-55.46
EPS:
-5.85
Net Cash Flow:
$223.75M
1W Performance:
-7.18%
1M Performance:
-5.26%
6M Performance:
+12.31%
1Y Performance:
+6.18%
1-Day Range:
$320.32
$326.45
1-Week Range:
$306.42
$349.07
52-Week Range:
$262.12
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| BIO | 324.60 | 9.06B | 2.58B | -778.69M | 223.75M | -5.85 |
| ABT | 117.19 | 201.08B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.91 | 147.64B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 91.51 | 134.72B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 84.62 | 107.85B | 33.00B | 4.29B | 5.50B | 2.71 |
| EW | 70.57 | 41.30B | 6.60B | 4.16B | 490.10M | 2.34 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-07-23 | Initiated | UBS | Buy |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jan-28-22 | Reiterated | Citigroup | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-17-18 | Initiated | Goldman | Buy |
| Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-16-18 | Downgrade | CL King | Buy → Neutral |
| Jul-13-17 | Initiated | Wells Fargo | Outperform |
| Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Hold |
| Oct-13-16 | Initiated | CL King | Buy |
| May-06-15 | Reiterated | Jefferies | Buy |
| Dec-18-09 | Initiated | Maxim Group | Buy |
| Nov-06-09 | Initiated | Jefferies & Co | Buy |
| Jul-17-09 | Initiated | Soleil | Buy |
| Sep-26-07 | Initiated | Banc of America Sec | Buy |
| Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
Thompson Siegel & Walmsley LLC Sells 83,227 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference - Business Wire
One Step RT-qPCR Kits Market Key Players AnalysisTakara Bio - openPR
Natixis Advisors LLC Increases Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Leukemia Screening Market Future Business Opportunities - openPR
Custom Antibody Services Market Report: Detailed Insights - openPR
Cell Signaling Market: Opportunities, Challenges, and Growth - openPR
Electrophoresis Reagents Market: Company Profiles, Segment - openPR
Hematology Testing Products Market Statistical Forecast - openPR
Biological Multiplex Assays Market to Witness Significant - openPR
IVD quality control Market Share, Trends, Top Players, Segments - openPR
Biochips Market Opportunities and Trends With Leading Key - openPR
DNA Extraction Kits Market Is Booming Worldwide 2024-2031 | - openPR
Cell Viability Assays Market Opportunities and Trends - openPR
Molecular Quality Controls Market Size Analysis and Regional - openPR
Protein Engineering Market Projected to Reach USD 7.39 Billion by 2032 with a CAGR of 14.72% - GlobeNewswire Inc.
Mawer Investment Management Ltd. Boosts Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Protein Chip Market Growth, Industry Development and Forecast - openPR
Genomic Biomarker Market 2024 Opportunity, Challenge, - openPR
Laboratory Mixer Market Strong Industry Growth, Business - openPR
Research Antibodies Market Report Outlines Revenue Share, SWOT - openPR
Genomic Biomarker Market Dynamics and Forecast Comprehensive - openPR
Bio-Rad Laboratories, Inc. (NYSE:BIO) Stake Lowered by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Sumitomo Mitsui Trust Group Inc. Trims Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Clinical Diagnostics Market to Reach $ 110.0 Billion by 2031 | - openPR
Multiplexed Diagnostics Market Share, Trends, Top Players, - openPR
Apoptosis Assays Market Analysis By Top KeyplayersMerck, - openPR
High-throughput Screening Technology Market Size and Regional An - News Channel Nebraska
Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock Holdings Boosted by Principal Financial Group Inc. - MarketBeat
Evaluation of a New Multimodal Anion Exchange Resin for Emerging Biotherapeutic Process Challenges - BioProcess Insider
Short Interest in Bio-Rad Laboratories, Inc. (NYSE:BIO) Declines By 20.8% - MarketBeat
Chromatography Systems Market Industry Detailed Exploration, - openPR
VAN ECK ASSOCIATES CORP's Strategic Acquisition in Bio-Rad Labor - GuruFocus.com
Chiral Chromatography Columns Market Overall Study Report - openPR
Dental Services Market Overall Study Report 2024-2032 | Agilent - openPR
Genomics Market Overall Study Report 2024-2032 | Agilent - openPR
SEC Form SC 13G filed by Bio-Rad Laboratories Inc. - Quantisnow
Entropy Technologies LP Acquires Shares of 4,200 Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
4,200 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Bought by Entropy Technologies LP - MarketBeat
Bio-Rad Demonstrates Leadership Position in the Oncology Market at Association for Molecular Pathology 2024 - Technology Networks
Protein A Resin Market Growth, Size, Trends, Shares, By Top - openPR
Brokerages Set Bio-Rad Laboratories, Inc. (NYSE:BIO) Target Price at $391.80 - MarketBeat
Lung Cancer Diagnostics Market Anticipated for Positive Growth - openPR
Biochips Market Is Booming Worldwide 2024-2031 | Illumina, - openPR
Bio-Rad Laboratories: This Undervalued Stock Offers Investors a Rare Combination - Morningstar
ICICI Prudential Asset Management Co Ltd Raises Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity? - Insider Monkey
PCR Systems Market Growth, Industry Development and Forecast - openPR
Thalassemia Testing Market Ready to Rise Sharply On Superior - openPR
Bio-Rad demonstrates leadership position in the oncology market at Association for Molecular Pathology 2024 - Cambridge Network
Biosensors Market Is Booming Worldwide 2024-2031 | Bio-Rad - openPR
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):